Central nervous system cancers: Clinical Practice Guidelines in Oncology™

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 5, 2008, Pages 456-504

  Brem, Steven S ^a   Bierman, Philip J ^a   Black, Peter ^a   Brem, Henry ^a   Chamberlain, Marc C ^a   Chiocca, Ennio A ^a   DeAngelis, Lisa M ^a   Fenstermaker, Robert A ^a   Friedman, Allan ^a   Gilbert, Mark R ^a   Glass, Jon ^a   Grossman, Stuart A ^a   Heimberger, Amy B ^a   Junck, Larry ^a   Linette, Gerald P ^a   Loeffler, Jay J ^a   Maor, Moshe H ^a   Moots, Paul ^a   Mrugala, Maciej ^a   Nabors, Louis Burt ^a   Newton, Herbert B ^a   Olivi, Alessandro ^a   Portnow, Jana ^a   Prados, Michael ^a   Raizer, Jeffrey J ^a   Shrieve, Dennis C ^a   Sills Jr , Allen K ^a   more..

^a NONE

Author keywords

Angiogenesis; Astrocytoma; Bevacizumab; Brain metastases; Brain tumor; Chemotherapy; Glioblastoma; Irinotecan; NCCN Clinical Practice Guidelines; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IRINOTECAN; LIPOSOMAL CYTARABINE; LOMUSTINE; METHOTREXATE; NITROSOUREA; PROCARBAZINE; RITUXIMAB; STEROID; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ALGORITHM; ASTROCYTOMA; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN SURGERY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; EPENDYMOMA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLIOBLASTOMA; HUMAN; INVASIVE CARCINOMA; LYMPHOMATOUS MENINGITIS; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; RADIATION DOSE FRACTIONATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD METASTASIS; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 44449123705     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0037     Document Type: Review

References (162)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;571:43-66.
2. Maher EA, McKee AC. Neoplasms of the central nervous system. In: Skarin AT, Canellos GP, eds. Atlas of Diagnostic Oncology, 3rd ed. London: Elsevier Science Limited; 2003.
3. Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998;42:1044-1055.
4. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-710.
5. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003:99:467-473.
6. Hentschel SJ, Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 2003;10:190-114.
7. Harsh GR VI, Levin VA, Gutin PH, et al. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 1987;21:615-621.
8. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978;49:333-343.
9. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22:1583-1588.
10. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60:853-860.
11. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998;41:1005-1011.
12. Walker MD, Green SB, Byar DP, et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-1329.
13. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001;19:509-518.
14. Fine HA, Dear BG, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597.
15. Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy for high-grade glioma. Cochrane Database Syst Rev 2002:CD003913.
16. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolamide for glioblastoma. N Engl J Med 2005;352:987-996.
17. Hegi ME, Diserens AC, Gorlia T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
18. Mollemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in Oligodendroglial tumors. Int J Cancer 2005;113:379-385.
19. Glantz M, Chamberlain MC, Liu Q, et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003;97:2262-2266.
20. Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer 2003;97:657-662.
21. Levin VA, Silva P, Hannigan J, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic glioma: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990:18:321-324.
22. Prados MD, Scott C, Curran WJ Jr, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemothetapy. J Clin Oncol 1999;17:3389-3395.
23. Brandes AA, Tosoni A, Basso U, et al. Second-line chemothetapy with irinotecan plus carmustine in glioblastoma recurrent or progressive aftet first-line temozolomide chemotherapy: a phase II study of the Gruppo ltaliano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004;22:4779-4786.
24. Reardon DA, Quinn JA, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005;103:329-338.
25. Brandes AA, Basso U, Reni M, et al. First-line chemotherapy with ctsplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 2004;22:1598-1604.
26. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729.
27. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-1012.
28. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44-48.
29. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegtadable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79-88.
30. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148:269-275; discussion 275.
31. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997;15:3121-3128.
32. Grossman SA, Hochberg F, Fisher J, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998;42:118-126.
33. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Williston Park) 2002;16(Suppl 7):33-40.
34. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002;8:2202-2209.
35. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-409.
36. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Research 2003;9:2940-2949.
37. Rowinsky EK. Paclitaxel pharmacology and other tumor types. Semin Oncol 1997;24(6 Suppl 19):S19-1-S19-12.
38. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-2714.
39. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-2722.
40. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2672-2771.
41. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent Oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26791. J Clin Oncol 2003;21:2525-2528.
42. Silvani A, Eoli M, Salmaggi A, et al. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 2004;66:203-208.
43. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007;25:3357-3361.
44. Shaw EG, Daumas-Duport C, Scheithaurer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853-861.
45. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001;95:735-745.
46. Soffietti R, Chio A, Giordana MT, et al. Prognostic factors in well differentiated cerebral astrocytomas in the adult. Neurosurgery 1989;26:686-692.
47. Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993;32:554-559.
48. Lo SS, Cho KH, Hall WA, et al. Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low-grade gliomas? Int J Cancer 2001;96(Suppl):71-78.
49. Kilic T, Ozduman K, Elmaci I, et al. Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas. J Clin Neurosci 2002;9:549-552.
50. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784-1791.
51. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002;52:316-324.
52. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985-990.
53. Shaw EG, Tatter SB, Lesser GJ, et al. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 2004;31:653-658.
54. Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol 2003;5:153-160.
55. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996;36:549-556.
56. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267-2276.
57. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646-651.
58. Shaw EG, Berkey B, Coons SW, et al. Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG) [abstract]. J Clin Oncol 2006;24(Suppl 1):58s. Abstract 1500.
59. Lo SS, Hall WA, Cho KH, et al. Radiation dose response for supratentorial low-grade glioma - institutional experience and literature review. J Neurol Sci 2003;214:43-48.
60. Nijjar TS, Simpson WJ, Gadalla T, et al. Oligodendroglioma: the Princess Margaret Hospital experience (1958-1984). Cancer 1993;71:4002-4006.
61. Cairncross JG, Ueki K, Zlatescu M, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
62. Lindegaard KF, Mork SJ, Eide GE, et al. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 1987;67:224-230.
63. Shaw EG, Scheithauer BW, O'Fallon JR, et al. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994;34:577-582.
64. Shaw EG, Scheithauer BW, O'Fallon JR, et al. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992;76:428-434.
65. Mork SJ, Lindegaard KF, Halvorsen TB, et al. Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985;63:881-889.
66. Yeh SA, Lee TC, Chen HJ, et al. Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 2002;54:1405-1409.
67. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-2021.
68. Buckner JC, Gesme D Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-255.
69. van den Bent M, Chinot OL, Cairncross JG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol 2003;5:128-138.
70. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-845.
71. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection and outcome. J Neurooncol 1997;34:85-101.
72. Buatti JM, Meeks SL, Ryken TC, et al. Low-grade gliomas: answering one question in a myriad of new questions [editorial]. J Clin Oncol 2002;20:2223-2224.
73. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18:636-645.
74. Vogelbaum M, Berkey B, Peereboom D, et al. RTOG 0131: phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas [abstract]. J Clin Oncol 2005;23:Abstract 1520.
75. Vogelbaum M, Berkey B, Peereboom D, et al. RTOG 0131: phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: relationship between 1p/19q status and progression-free survival [abstract]. J Clin Oncol 2006;24:62s. Absttact 1517.
76. van den Bent MJ. New perspectives for the diagnosis and treatment of oligodendroglioma. Expert Rev Anticancer Ther 2001;1:348-356.
77. van den Bent MJ. Advances in the biology and treatment of oligodendrogliomas. Curr Opin Neurol 2004;17:675-680.
78. Chinot O, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001;19:2449-2455.
79. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
80. De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Philadelphia; Lippincott Williams & Wilkins; 2004.
81. Packer RJ, Hoffman HJ, Friedman HS, et al. Tumors of the fourth ventricle. In: Levin VA, ed. Cancer in the Nervous System. New York: Churchill Livingstone; 1996:153-156.
82. Vanuytsel LJ, Bessell EM, Ashley SE, et al. Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:313-319.
83. Goldwein JW, Corn BW, Finlay JL, et al. Is craniospinal irradiation required to cute children with malignant (anaplastic) intracranial ependymomas? Cancer 1991;67:2766-2771.
84. Wallner KE, Wara WM, Sheline GE, et al. Intracranial ependymomas: results of treatment with partial or whole brain irradiation without spinal irradiation. Int J Radiat Oncol Biol Phys 1986;12:1937-1941.
85. Vanuytsel L, Brada M. The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 1991;21:825.
86. Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005;61:387-391.
87. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-3617.
88. DeVita VT Jr, Hellman S, Rosenberg SA. Principles & Practice of Oncology, 6th Edition. Philadelphia: Lippincott Williams & Wilkins; 2000.
89. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280:1485-1489.
90. Auchter RM, Lamond JP, Alexander E, et al. A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 1996;35:27-35.
91. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-2107.
92. Hofmann M, Kiecker F, Wurm R, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006;76:59-64.
93. Gajewski TF. Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol 2004;22:580-581.
94. Krown SE, Niedzwiecki D, Hwu WJ, et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 2006;107:1883-1890.
95. Laber DA, Okeke RI, Arce-Lara C, er al. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol 2006;132:611-616.
96. Weinberg JS, Lang FF, Sawaya R. Surgical management of brain metastases. Curr Oncol Rep 2001;3:476-483.
97. Patchell RA, Tibbs P, Walsh JW, et al. A randomized trial of surgery in the treatment of single brain metastases to the brain. N Engl J Med 1990;322:494-500.
98. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of tteatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711-717.
99. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-2491.
100. Bindal AK, Bindal RK, Hess KR, et al. Surgery versus radiosurgery in rhe treatment of brain metastasis. J Neurosurg 1996;84:748-754.
101. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-1672.
102. Lang FF, Wildrick DM, Sawaya R. Management of cerebral metastases: the role of surgery. Cancer Control 1998;5:124-129.
103. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. J Radiat Oncol Biol Phys 2000;47:291-298.
104. Tsao MN, Lloyd NS, Wong RK, et al Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005;31:256-273.
105. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884-898.
106. van den Bent MJ. The role of chemotherapy in brain metastases. Eur J Cancer 2003;39:2114-2120.
107. Lang FF, Chang EL, Abi-Said D, et al. Metastatic brain tumors. In: Winn HR, ed. Youman's Neurological Surgery, 5th ed. Philadelphia: Saunders; 2004:1077-1097.
108. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980;6:1-9.
109. Alexander E, Moriarty TM, Davis RB, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995;87:34-40.
110. Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006;78:255-260.
111. Jayson GC, Howell A. Carcinomatous meningitis in solid tumors. Ann Oncol 1996;7:773-786.
112. Chamberlain MC. Carcinomatous meningitis. Arch Neurol 1997;54:16-17.
113. Grossman SA, Krabak ML. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103-119.
114. Jaeckle KA, Phuphanich S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001;84:157-163.
115. Bokstein F, Lossos A, Lossos IS, et al. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002;43:587-593.
116. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998;16:1561-1567.
117. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release vs a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17:3110-3116.
118. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management of, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995;75:2919-2931.
119. Chamberlain MC, Kormanik PR, Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997;35:55-64.
120. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-1104.
121. DeAngelis LM. Current management of primary central nervous system lymphoma. Oncology 1995;9:63-71.
122. Coté TR, Manns A, Hardy CR, et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst 1996;88:675-679.
123. Traweek ST. Nervous system involvement by lymphoma, leukemia and other hematopoietic cell proliferations. In: Bigner DD, McLendon RE, Bruner JM, eds. Russell & Rubinstein's Pathology of Tumors of the Nervous System. 6th ed. London: Arnold Press; 1998:195-237.
124. Johnson BA, Fram EK, Johnson PC, et al. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. Am J Neuroradiol 1997;18:563-572.
125. DeAngelis LM. Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. Ann Neurol 1993;33:308-311.
126. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-5043.
127. DeAngelis LM, Yahalom J, Heinemann MH, et al. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990;40:80-86.
128. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma rreated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-1590.
129. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
130. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111-Indium-DTPA CSF flow studies. Neurology 1991;41:1765-1769.
131. Grossman SA, Moynihan TJ. Neoplastic meningitis. Neurol Clin N Am 1991;9:843-856.
132. Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24:4570-4574.
133. Gabbai AA, Hochberg FH, Linggood RM, et al. High-dose methotrexate for non-AIDS primary central netvous system lymphoma. Report of 13 cases. J Neurosurg 1989;70:190-194.
134. Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary centtal nervous system lymphomas. J Neurosurg 1999;91:221-230.
135. DeAngelis LM. Primary central nervous system lymphomas. Curr Treat Options Oncol 2001;2:309-318.
136. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-4648.
137. Freilich RJ, Delattre JY, Monjour A, et al. Chemotherapy without radiation therapy as inirial treatment for primary CNS lymphoma in older patients. Neurology 1996;46:435-439.
138. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-1049.
139. Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507-1513.
140. Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004;101:139-145.
141. Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-903.
142. Hoang-Xuan K, Camilleri-Broet S, Soussain C. Recent advances in primary CNS lymphoma. Curr Opin Oncol 2004b;16:601-606.
143. Pitini V, Baldari S, Altavilla G, et al. Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and temozolomide. J Neurooncol 2007;83:291-293.
144. Voloschin AD, Betensky R, Wen PY, et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008;86:211-215.
145. Younes A, Preti HA, Hagemeister FB, et al. Paclitaxel plus topotecan tteatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001;12:923-927.
146. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996;14:534-542.
147. Nelson KA, Walsh D, Abdullah O, et al. Common complications of advanced cancer. Semin Oncol 2000;27:34-44.
148. Ruckdeschel J. Spinal cord compression: problems common to cancer and it's therapy: part II. In: Abeloff M, Armitage J, Lichter A, eds. Clinical Oncology. New York: Churchill Livingston; 1995;36:811-819.
149. Zerick W, Fessler R, Cahill D. Metastatic spine tumors: an overview. In: Rea GL, ed. Spine Tumors. American Association of Neurological Surgeons; 1994:7-23.
150. York J, Wildrick D, Gokaslan Z. Metastatic tumors. In: Benzel EC, Stillerman CB, eds. The Thoracic Spine. St. Louis: Quality Medical Publishing, Inc; 1999:392-411.
151. Vrionis FD, Miguel R. Management of spinal metastases. Seminars in Pain Medicine 2003;1:25-33.
152. Sørensen PS, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. 1994;30:22-27.
153. Sundaresan N, Steinberger A, Moore F, et al. Surgical management of primary metastatic tumors of the spine. In: Schmidek HH. Operarive Neurosurgical Techniques: Indications, Methods, and Results, 4th ed, Vol 2. Philadelphia: W. B. Saunders Company; 2000;2146-2170.
154. Vrionis FD, Small J. Surgical management of metastatic spinal neoplasms. Neurosurg Focus 2003;15;E12.
155. Wang JC, Boland P, Mitra N, et al. Single-stage posterolateral transpedicular approach for resection of epidural metastatic spine tumors involving the vertebral body with circumferential reconstruction: results in 140 patients. J Neurosurg Spine 2004;1:287-298.
156. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression by metastatic cancer: a randomized trial. Lancet 2005;366:643-648.
157. Gokaslan Z, York J, Walsh G, et al. Transthoracic vertebrectomy for metastatic spinal tumors. J Neurosurg 1998;89:599-609.
158. Fourney DR, Schomer DE, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003;98:21-30.
159. Siegal T, Siegal T. Surgical management of malignant epidural tumors compressing the spinal cord. In: Schmidek HH. Operative Neurosurgical Techniques: Indications, Methods, and Results, 4th ed, Vol 2. Philadelphia: W B. Saunders Company; 2000;2171-2197.
160. Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 2005;23:3366-3375.
161. Kwok Y, Regine WF, Patchell RA. Radiation therapy alone for spinal cord compression: time to improve upon a relatively ineffective status quo. J Clin Oncol 2005;23:1-3.
162. Lohlaw DA, Perry J, Chambers A, et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005;23:2028-2037.